- Home
- NBTX vs FENC Comparison
NBTX vs FENC Comparison
Compare NBTX & FENC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NBTX
- FENC
- Stock Information
- Founded
- NBTX 2003
- FENC 1996
- Country
- NBTX France
- FENC United States
- Employees
- NBTX N/A
- FENC N/A
- Industry
- NBTX Biotechnology: Pharmaceutical Preparations
- FENC Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NBTX Health Care
- FENC Health Care
- Exchange
- NBTX Nasdaq
- FENC Nasdaq
- Market Cap
- NBTX 178.7M
- FENC 156.9M
- IPO Year
- NBTX 2020
- FENC 2001
- Fundamental
- Price
- NBTX $3.41
- FENC $6.02
- Analyst Decision
- NBTX Strong Buy
- FENC Strong Buy
- Analyst Count
- NBTX 1
- FENC 2
- Target Price
- NBTX $8.00
- FENC $14.00
- AVG Volume (30 Days)
- NBTX 7.6K
- FENC 52.7K
- Earning Date
- NBTX 04-02-2025
- FENC 05-20-2025
- Dividend Yield
- NBTX N/A
- FENC N/A
- EPS Growth
- NBTX N/A
- FENC N/A
- EPS
- NBTX N/A
- FENC N/A
- Revenue
- NBTX N/A
- FENC $47,538,000.00
- Revenue This Year
- NBTX N/A
- FENC $2.68
- Revenue Next Year
- NBTX $221.06
- FENC $71.63
- P/E Ratio
- NBTX N/A
- FENC N/A
- Revenue Growth
- NBTX N/A
- FENC 123.69
- 52 Week Low
- NBTX $2.76
- FENC $3.96
- 52 Week High
- NBTX $7.51
- FENC $10.07
- Technical
- Relative Strength Index (RSI)
- NBTX 55.19
- FENC 61.18
- Support Level
- NBTX $3.26
- FENC $5.85
- Resistance Level
- NBTX $3.65
- FENC $6.61
- Average True Range (ATR)
- NBTX 0.19
- FENC 0.34
- MACD
- NBTX 0.03
- FENC 0.09
- Stochastic Oscillator
- NBTX 43.75
- FENC 82.70
About NBTX Nanobiotix S.A.
Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.
About FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.